Dr. Paco Eduardo Bravo, MD

Dr. Bravo practices at Good Shepherd Penn Partners - HOPD (3400 Spruce Street, White Bldg 1st Flr) in Philadelphia, Pennsylvania.

Dr. Bravo's NPI, 1215140900, was assigned on May 8, 2007. Dr. Bravo holds Pennsylvania license MD462995.

Dr. Bravo's primary practice is Good Shepherd Penn Partners - HOPD (3400 Spruce Street, White Bldg 1st Flr), at 3400 Spruce Street, White Bldg 1st Flr, Philadelphia, PA 19104.

Dr. Bravo's primary practice is Good Shepherd Penn Partners - HOPD (3400 Spruce Street, White Bldg 1st Flr) in Philadelphia, Pennsylvania. Dr. Bravo is also affiliated with Hospital of the University of Pennsylvania. The medical group on file is Penn Medicine Lancaster General Health. Dmand AI also links Dr. Bravo to 3 more hospitals and 2 medical groups, each named with a free account. Dr. Bravo's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Bravo practices, 5 sites in all. Vendor and product names are available with a free account.

Nuclear cardiology is Dr. Bravo's primary specialty in the NPI Registry, under taxonomy code 207UN0901X. Dr. Bravo is licensed in Pennsylvania.

CMS data shows 1,380 Medicare services from Dr. Bravo across 13 procedure codes in 2024, for 772 Medicare patients. Medicare paid $57,348 for them.

CMS counts 772 Medicare patients who saw Dr. Bravo in 2024. The largest group is 65 to 74, with 361 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 10% are also on Medicaid. Their average risk score is 1.98, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Bravo's median patient age at 64, with 47% women.

Dr. Bravo accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 99 papers to Dr. Bravo, published from 2010 to 2025. 2021 was the busiest year, with 11. The most frequent topics are Positron-Emission Tomography, Cardiomyopathies and Sarcoidosis. Dr. Bravo has published most often in J Nucl Cardiol. Dr. Bravo's most frequent co-authors are Frank Michael Bengel, MD, Mahesh Krishna Vidula, MD and Navkaranbir S. Bajaj, MD.

Dmand AI links Dr. Bravo to 1 clinical trial. 1 is still active or recruiting. Conditions studied include Alcohol Drinking and Drinking Behavior.

CMS Open Payments shows 13 general payments to Dr. Bravo from 6 drug and device companies from 2019 to 2025. Consulting fees make up the largest share, 56% of the total. Eli Lilly and Company paid the most, $575.